Global Point-of-Care Infectious Disease Diagnostics/Testing Market Size By Type (HIV POC, Clostridium difficile POC), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 203...

The Global Point-of-Care Infectious Disease Diagnostics/Testing Market was valued at USD 8.5 billion in 2023 and is expected to surpass USD 14.7 billion by 2031, growing at a CAGR of 7.2% during the forecast period from 2023 to 2031. The increasing demand for rapid and accurate infectious disease diagnostics is fueling market growth, particularly in emergency care settings, remote locations, and low-resource areas. Point-of-care (POC) testing allows for quicker clinical decisions and timely treatment, reducing the burden on central laboratories.

Technological advancements in microfluidics, biosensors, and molecular diagnostics have significantly improved the accuracy and reliability of POC infectious disease tests, expanding their adoption in hospitals, clinics, and home-care settings.

Market Drivers

Rising Incidence of Infectious Diseases:

The increasing prevalence of infectious diseases such as HIV, tuberculosis, hepatitis, and respiratory infections is driving demand for rapid diagnostic solutions. The COVID-19 pandemic further highlighted the need for accessible, on-the-spot testing.

Growing Preference for Rapid & Decentralized Testing:

POC testing allows for real-time disease detection at the patient site, minimizing turnaround time and facilitating quicker clinical decisions, making it an essential tool for global healthcare systems.

Technological Advancements in Diagnostics:

Innovations such as portable PCR devices, CRISPR-based testing, and AI-powered diagnostic tools are improving test accuracy and efficiency, driving market adoption.

Increasing Investments in Healthcare Infrastructure:

Government initiatives and funding programs aimed at improving infectious disease management, particularly in low- and middle-income countries (LMICs), are fueling market expansion.

Market Restraints

High Cost of Advanced POC Devices:

Despite their efficiency, high costs associated with molecular POC diagnostic devices limit adoption, especially in resource-limited settings.

Regulatory and Compliance Challenges:

Stringent regulatory frameworks for new diagnostic devices often delay approvals, impacting market entry for new players.

Limited Awareness and Infrastructure in Emerging Regions:

Many developing countries lack adequate healthcare infrastructure, trained personnel, and awareness about the benefits of rapid POC diagnostics.

Market Opportunities

Expansion in Emerging Markets:

Asia-Pacific, Latin America, and Africa present lucrative opportunities due to increasing healthcare investments and growing awareness of rapid infectious disease diagnostics.

Integration of AI and IoT in POC Testing:

AI-powered diagnostic tools and IoT-enabled connected POC devices are revolutionizing real-time disease monitoring and data sharing, improving patient outcomes.

Rising Adoption of Home-Based POC Testing:

The growing preference for self-testing kits for infections like HIV, COVID-19, and STDs is creating significant growth prospects.

Market Segmentation Insights

Market by System Type

Molecular Diagnostics (PCR, Isothermal Amplification)

Immunoassay-Based POC Testing

Microfluidic-Based Systems

Biosensor-Based Diagnostics

Molecular diagnostics held the largest market share in 2023, driven by the high demand for PCR-based rapid infectious disease detection. Meanwhile, biosensor-based POC testing is expected to grow at the fastest CAGR, owing to its portability, real-time monitoring capabilities, and affordability.

Market by End-Use

Hospitals & Clinics

Diagnostic Laboratories

Home-Care Settings

Government & Public Health Programs

Hospitals and clinics accounted for over 50% of the market share in 2023, due to their essential role in early disease detection and treatment management. However, the home-care segment is expected to witness the highest growth, driven by the rising availability of at-home self-testing kits.

Market by Regional Insights

North America led the market in 2023 due to advanced healthcare infrastructure, high healthcare expenditure, and the presence of key market players.

Asia-Pacific is expected to witness the fastest growth, fueled by rising investments in healthcare, increasing awareness of POC diagnostics, and a high burden of infectious diseases in countries like India and China.

Europe holds a significant market share, driven by government funding and adoption of digital healthcare technologies.

Competitive Landscape

Key players in the Global Point-of-Care Infectious Disease Diagnostics/Testing Market include:

Abbott Laboratories

Siemens Healthineers

Roche Diagnostics

BD (Becton, Dickinson and Company)

Danaher Corporation

bioMérieux

Chembio Diagnostics

Qiagen

Thermo Fisher Scientific

Quidel Corporation

Market leaders are focusing on new product launches, strategic partnerships, and geographic expansion to maintain their competitive edge.

Key Market Developments:

2023: Abbott launched a next-generation portable molecular POC testing device for infectious diseases, enhancing rapid diagnosis in remote areas.

2024: Roche Diagnostics collaborated with government health agencies to provide affordable POC testing solutions in LMICs.

2025: Siemens Healthineers introduced AI-driven POC testing kits for real-time infectious disease detection, improving diagnostic accuracy and efficiency.

Scope of Work – Global Point-of-Care Infectious Disease Diagnostics/Testing Market